1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414:782-7.

2. King H, Aubert RE, Herman, W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-31.

3. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004; 33(2):283-303.

4. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.

5. Desvergne B, Michalik L, Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 2004; 18(6):1321-32.

6. Kersten S, Desvergne B, Wahli W. Role of PPARs in health and disease. Nature 2000; 405:421-4.

7. Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-y target genes related to lipid storage in vivo. Diabetes Care 2004; 27(7):1660-7.

8. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116(7):1784-92.

9. Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2005.

10. Actos (Prescribing information). Lincolnshire, IL: Takeda; Indianapolis, IN: Elli Lilly Company, 2002.

11. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23(11): 1605-11.

12. Lebovitz HE, Dole JF, Patwardhan R, et al. The Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes [erratum appears in J Clin Endocrinol Metab 2001; 86(4):1659]. J Clin Endocrinol Metab 2001; 86(1):280-8.

13. UK Prospective Diabetes Study Group. 1995 UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44:1249-58.

14. Kahn SE, Haffner SM, Heise MA, et al. for the ADOPT Study Group. Glycemic durability of rosiglitazone. N Engl J Med 2006; 355:2427-43.

15. Vongthavaravat V, Wajchenberg BL, Waitman JN, et al. 125 Study Group. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Curr Med Res Opin 2002; 18(8):456-61.

16. Barnett AH, Grant PJ, Hitman GA, et al. Indo-Asian Trial Investigators. Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients. Diabet Med 2003; 20(5):387-93.

17. Hanefeld M, Brunetti P, Schernthaner GH, et al. QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27(1):141-7.

18. Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005; 69(1):5-13.

19. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283 (13):1695-702.

20. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22(12):395-409.

21. Jones TA, Sautter M, Van Gaal LF, et al. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5(3):163-70.

22. Bell DS, Ovalle F. Long-term glycaemic efficacy and weight changes associated with thiazolidi-nediones when added at an advanced stage of type 2 diabetes. Diabetes Obes Metab 2006; 8(1): 110-5.

23. Raskin P, Rendell M, Riddle MC, et al. The Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24(7):1226-32.

24. Rosenstock J, Einhorn D, Hershon K, et al. Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomized, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56(4):251-7.

25. Buch HN, Baskar V, Barton DM, et al. Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes. Diabet Med 2002; 19(7):572-4.

26. Purnell JQ, Dev RK, Steffes MW, et al. Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. Diabetes 2003; 52:2623-9.

27. Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes Care 2005; 28(7):1562-7.

28. Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15:193-203.

29. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Eng J Med 1994; 331:1188-98.

30. Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:3299-306.

31. Takino H, Okuno S, Uotani S, Yano M, Matsumoto K, Kawasaki E, Takao Y, Yamasaki H, Yamaguchi Y, Akazawa S. Increased insulin responsiveness after CS-045 treatment in diabetes associated with Werner's syndrome. Diabetes Res Clin Pract 1994; 24:167-72.

32. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes—the thiazolidinediones or insulin sensitizers. Annu Rev Med 2001; 52:239-57.

33. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006; 368:1096-105.

34. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001; 44(12):2210-9.

35. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88(4):1637-45.

36. Levy J, Atkinson AB, Bell PM, et al. ß-cell deterioration determines the onset and rate of progression of secondary dietary failure in Type 2 diabetes mellitus: the 10-year follow-up of the Belfast diet study. Diabet Med 1998; 15:290-6.

37. Dubois M, Pattou F, Kerr-Conte J, et al. Expression of peroxisome proliferator-activated receptory (PPARy) in normal human pancreatic islet cells. Diabetologia 2000; 43(9):1165-9.

38. Prigeon RL, Kahn SE, Porte D. Effect of troglitazone on B cell function, insulin sensitivity and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endo Metab 1998; 83(3):819-923.

39. Kubo K. Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. Endocr J 2002; 49(3):323-8.

40. Juhl CB, Hollingdal M, Porksen N, et al. Influence of rosiglitazone treatment on ß-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 2003; 88(8):3794-800.

41. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic ß-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51:2796-803.

42. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic ß-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55(2):517-22.

43. Venkat Narayan KM. The diabetes pandemic: looking for the silver lining. Clin Diabetes 2005; 23: 51-2.

44. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393-403.

45. Knowler WC, Hamman RF, Edelstein SL, et al. Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54(4):1150-6.

46. Garg A. Dyslipoproteinemia and diabetes. Endocr Metab Clin North Am 1998; 27(3):613-26.

47. Ginsberg Hn. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106:453-8.

48. Freed MI, Ratner R, Marcovina SM, et al. Rosiglitazone Study 108 investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90(9):947-52.

49. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23(11): 1605-11.

50. Crawford RS, Mudaliar SR, Henry RR, Chait A. Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone. Diabetes 1999; 48(4):783-90.

51. Rosenblatt S, Miskin B, Glazer NB. Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12(5):413-23.

52. Goldberg RB, Kendall DM, Deeg MA, et al. GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28(7):1547-54.

53. Matsumoto K, Miyake S, Yano M, et al. Increase of lipoprotein (a) with troglitazone. Lancet 1997; 350:1748-9.

54. Nagai Y, Abe T, Nomura G. Does pioglitazone, like troglitazone, increase serum levels of lipoprotein(a) in diabetic patients? Diabetes Care 2001; 24:408-9.

55. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351(11):1106-18.

56. Spiegelman BM. PPAR : adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-14.

57. Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor-y have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100:3149-53.

58. Mori Y, Murakawa Y, Okada K, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999; 22(6):908-12.

59. Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22(2):288-93.

60. Carey DG, Cowin GJ, Galloway GJ, et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res 2002; 10(10):1008-15.

61. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51(3):797-802.

62. Ghazzi MN, Perez JE, Antonucci TK, et al. The Troglitazone Study Group: cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997; 46:433-9.

63. Asakawa M, Takano H, Nagai T, et al. Peroxisome proliferator-activated receptor g plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002; 105(10): 1240-6.

64. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-g agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106(24):3126-32.

65. St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25(11):2058-64.

66. Horio T, Suzuki M, Suzuki K, et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005; 18(7):949-57.

67. Hallsten K, Virtanen KA, Lonnqvist F, et al. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. Diabet Med 2004; 21 (12):1280-7.

68. Lautamaki R, Airaksinen KE, Seppanen M, et al. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16 week randomized, doubleblind, placebo-controlled study. Diabetes Care 2005; 54(9):2787-94.

69. McMahon GT, Plutzky J, Daher E, et al. Effect of a peroxisome proliferator-activated receptor-g agonist on myocardial blood flow in type 2 diabetes. Diabetes Care 2005; 28(5):1145-50.

70. Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Am J Hypertens 1995; 8:316-20.

71. Sarafidis PA, Lasaridis AN. Actions of peroxisome proliferator-activated receptors-g agonists explaining a possible blood pressure-lowering effect. Am J Hypertens 2006; 19(6):646-53.

72. Baron AD. Hemodynamic actions of insulin. Am J Physiol 1994; 267:E187-202.

73. Watanabe K, Komatsu J, Kurata M, et al. Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension. J Hypertens 2004; 22(9):1761-8.

74. Qayyum R, Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens (Greenwich) 2006; 8(1):19-28.

75. American Diabetes Association. Position statement: diabetic nephropathy. Diabetes Care 2000; 23 (Suppl. 1):S69-72.

76. Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 2000; 14(5):250-4.

77. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003; 17(1):7-12.

78. Maeda A, Horikoshi S, Gohda T, et al. Pioglitazone attenuates TGF-ß (1)-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)g. Cell Biol Int 2005; 29(6):422-8.

79. Duez H, Fruchart JC, Staels B. PPARs in inflammation, atherosclerosis and thrombosis. J Cardiovasc Risk 2001; 8(4):187-94.

80. Hsueh WA, Javkson S, Law RE. Control of vascular cell proliferation and migration by PPARg. Diabetes Care 2001; 24(2):392-7.

81. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-g is a negative regulator of macrophage activation. Nature 1998; 391:79-82.

82. Jiang C, Ting AT, Seed B. PPAR-g agonists inhibit production of monocyte inflammatory cytokines. Nature 2001; 391:82-6.

83. Chawla A, Boisvert WA, Lee CH, et al. A PPAR g-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001; 7(1):161-71.

84. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106(6): 679-84.

85. Koshiyama H, Shimono D, Kuwamura N, et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86:3452-6.

Choi D, Kim SK, Choi SH, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27(11):2654-60. Dormandy JA, Charbonnel B, Eckland DJ, et al. The PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366:1279-89.

Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005; 48 (9):1726-35.

Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81 (9):3299-306.

Brettenthaler N, De Geyter C, Huber PR, et al. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89(8):3835-40.

Rautio K, Tapanainen JS, Ruokonen A. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod 2006; 21(6): 1400-7.

Hadigan C, Miller K, Corcoran C. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84: 1932-7.

Gelato MC, Mynarcik DC, Quick JL, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 2002; 31(2):163-70.

Walli R, Michl GM, Muhlbayer D, et al. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med 2000; 199(5):253-62. van Wijk JP, de Koning EJ, Cabezas MC, et al. Related comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005; 143(5):337-46. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91(9):3349-54.

Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 2004; 27(10):982-91.

Chaffer CL, Thomas DM, Thompson EW, et al. PPARy independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006; 6:53.

Panigrahy D, Singer S, Shen LQ, et al. PPARy ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002; 110(7):923-32.

Kulke MH, Demetri GD, Sharpless NE, et al. A phase II study of troglitazone, an activator of the PPARy receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002; 8(5):395-9.

Smith MR, Manola J, Kaufman DS, et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004; 101:1569-74.

Seed B. PPAR- and colorectal carcinoma: conflicts in a nuclear family. Nat Med 1998; 4:1004-5. Clark RB. The role of PPARs in inflammation and immunity. J Leukoc Biology 2002; 71(3):388-400. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49(10): 497-505.

Lewis JD, Lichtenstein GR, Stein RB, et al. An open-label trial of the PPAR-y ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001; 96(12):3323-8.

Deng L, Wang F, Li H. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 2005; 61(11):831-6.

Mudaliar S, Henry RR. Thiazolidinediones, peripheral edema and type 2 diabetes: incidence, pathophysiology and clinical implications. Endocr Pract 2003; 9(5):406-16.

Zhang H, Zhang A, Kohan DE, et al. Related Collecting duct-specific deletion of peroxisome proliferator-activated receptor y blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A 2005; 102(26):9406-11.

Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARy stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11(8):861-6. Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006; 29(3):510-4.

Al-Salman J, Arjomand H, Kemp DG. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Int Med 2000; 132(2):121-4.

113. Pinto AG, Cummings OW, Chalasani N. Severe but reversible cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002; 137(10):857.

114. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25(5):815-21.

115. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355:2297-307.

116. Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with Type 2 diabetes: a retrospective cohort study. Diabetes Care 2003; 26:2983-9.

117. Karter AJ, Ahmed AT, Liu J, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005; 22(8):986-93.

118. ADA/AHA CONSENSUS, Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108:2941-8.

Weight Loss All Star

Weight Loss All Star

Are you looking to lose weight or even just tone up? What is stopping you from having the body you want and help you feel great at the same time? I created Weight Loss All-Star for all those wanting to lose weight, and keep the weight off. I know how hard it is to do diets and stick with them, and get the motivation to get up and exercise.

Get My Free Ebook

Post a comment